KEYCORP /NEW/
KEYCORP /NEW/ (KEY) Stock News
The latest KEY headlines and market coverage — 3 recent stories, updated throughout the day.
- Benzinga·
EDWARD SMOLYANSKY, KEY LWAY SHAREHOLDER: TERMINATION OF POISON PILL MARKS IMPORTANT INFLECTION POINT FOR LIFEWAY SHAREHOLDERS AS GOVERNANCE QUESTIONS MOUNT AHEAD OF THE ELECTION
Edward Smolyansky, largest shareholder and former COO of Lifeway Foods, criticizes the Board's governance, stating the poison pill was only terminated after ISS recommended voting against all directors. He highlights a pattern of reactive governance, the reversal of a board refresh process, and calls for shareholders to vote against incumbent directors at the June 17 Annual Meeting to register dissatisfaction with the Board's conduct.
- Benzinga·
KEYCORP DECLARES QUARTERLY CASH DIVIDEND ON COMMON SHARES AND PREFERRED STOCKS AND ANNOUNCES NEW SHARE REPURCHASE PROGRAM
KeyCorp announced a quarterly cash dividend of $0.205 per share on common stock payable June 15, 2026, along with dividends on multiple preferred stock series. The company also authorized a new $3.0 billion share repurchase program, replacing its previous $1.0 billion authorization with approximately $280 million remaining.
- GlobeNewswire Inc.·
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
Erasca announced a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015, a pan-RAS molecular glue, in combination with Merck's pembrolizumab (KEYTRUDA®) for treating RAS-mutant solid tumors. The AURORAS-1 Phase 1 trial showed favorable safety, tolerability, and clinical responses at low doses. Merck will supply pembrolizumab at no cost to support the proof-of-concept study.